- Home
- DIBS vs UNCY Comparison
DIBS vs UNCY Comparison
Compare DIBS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- UNCY
- Stock Information
- Founded
- DIBS 2000
- UNCY 2016
- Country
- DIBS United States
- UNCY United States
- Employees
- DIBS N/A
- UNCY N/A
- Industry
- DIBS Catalog/Specialty Distribution
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- DIBS Consumer Discretionary
- UNCY Health Care
- Exchange
- DIBS Nasdaq
- UNCY Nasdaq
- Market Cap
- DIBS 88.1M
- UNCY 91.0M
- IPO Year
- DIBS 2021
- UNCY 2021
- Fundamental
- Price
- DIBS $2.67
- UNCY $6.34
- Analyst Decision
- DIBS Hold
- UNCY Strong Buy
- Analyst Count
- DIBS 1
- UNCY 4
- Target Price
- DIBS N/A
- UNCY $6.38
- AVG Volume (30 Days)
- DIBS 123.4K
- UNCY 867.0K
- Earning Date
- DIBS 08-05-2025
- UNCY 08-13-2025
- Dividend Yield
- DIBS N/A
- UNCY N/A
- EPS Growth
- DIBS N/A
- UNCY N/A
- EPS
- DIBS N/A
- UNCY N/A
- Revenue
- DIBS $88,740,000.00
- UNCY N/A
- Revenue This Year
- DIBS $3.02
- UNCY N/A
- Revenue Next Year
- DIBS $6.51
- UNCY $1,458.53
- P/E Ratio
- DIBS N/A
- UNCY N/A
- Revenue Growth
- DIBS 4.93
- UNCY N/A
- 52 Week Low
- DIBS $2.30
- UNCY $2.02
- 52 Week High
- DIBS $5.00
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- DIBS 50.20
- UNCY 48.29
- Support Level
- DIBS $2.53
- UNCY $4.70
- Resistance Level
- DIBS $2.86
- UNCY $7.58
- Average True Range (ATR)
- DIBS 0.18
- UNCY 1.20
- MACD
- DIBS -0.00
- UNCY -0.07
- Stochastic Oscillator
- DIBS 49.59
- UNCY 26.03
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.